Histone deacetylase inhibitor depsipeptide represses nicotinamide N-methyltransferase and hepatocyte nuclear factor-1β gene expression in human papillary thyroid cancer cells

Thyroid

Volumn 16, Issue 2, 2006, Pages 151-160

  Xu, Jimin ^a   Hershman, Jerome M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CELL DNA; CYCLOHEXIMIDE; DEPSIPEPTIDE; HEPATOCYTE NUCLEAR FACTOR 1BETA; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; NICOTINAMIDE METHYLTRANSFERASE; PROTEASOME INHIBITOR; SODIUM IODIDE SYMPORTER;

ARTICLE; BINDING SITE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME MECHANISM; ENZYME STABILITY; GENE ACTIVITY; GENE EXPRESSION REGULATION; GENE MUTATION; GENE REPRESSION; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS INHIBITION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID PAPILLARY CARCINOMA; TIME; TRANSCRIPTION INITIATION;

BLOTTING, WESTERN; CARCINOMA, PAPILLARY; CATALYSIS; CELL LINE, TUMOR; CELL NUCLEUS; DEPSIPEPTIDES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HISTONE DEACETYLASES; HUMANS; MODELS, STATISTICAL; MUTATION; NICOTINAMIDE N-METHYLTRANSFERASE; PLASMIDS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THYROID NEOPLASMS; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 33645471818     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.151     Document Type: Article

References (49)

1. Aksoy S, Szumlanski CL, Weinshilboum RM 1994 Human liver nicotinamide N-methyltransferase, cDNA cloning, expression, and biochemical characterization. J Biol Chem 269:14835-14840.
2. Souto JC, Blanco-Vaca F, Soria JM, Buil A, Almasy L, Ordonez-Llanos J, M Martin-Campos J, Lathrop M, Stone W, Blangero J, Fontcuberta J 2005 A genome-wide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: Results from the GAIT Project. Am J Hum Genet 76:925-933.
3. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA 2002 Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 277:45099-45107.
4. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W 2001 Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137-148.
5. Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA 2001 hSIRZ(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149-159.
6. Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA 2003 Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423:181-185.
7. Akalin E, Hendrix RC, Polavarapu RG, Pearson TC, Neylan JF, Larsen CP, Lakkis FG 2001 Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation 72:948-953.
8. Aoyama K, Matsubara K, Kondo M, Murakawa Y, Suno M, Yamashita K, Yamaguchi S, Kobayashi S. 2001 Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurosci Lett 298:78-80.
9. Fukushima T, Kaetsu A, Lim H, Moriyama M 2002 Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease. Exp Toxicol Pathol 53:469-473.
10. Parsons RB, Smith SW, Waring RH, Williams AC, Ramsden DB 2003 High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease. Neurosci Lett 342:13-16.
11. Hanazawa Y, Sato K, Kuroiwa N, Ogawa M, Kuriyama A, Asanagi M, Kato N, Moriyama Y, Horitsu K, Fujimura S 1994 Characterization of nicotinamide methyltransferase in livers of mice bearing Ehrlich ascites tumors: Preferential increase of activity. Tumour Biol 15:7-16.
12. Nakagawa K, Miyazaki M, Okui K, Kato N, Moriyama Y, Fujimura S 1991 N1-methylnicotinamide level in the blood after nicotinamide loading as further evidence for malignant tumor burden. Jpn J Cancer Res 82:1277-1283.
13. Okamura A, Ohmura Y, Islam MM, Tagawa M, Horitsu K, Moriyama Y, Fujimura S 1998 Increased hepatic nicotinamide N-methyltransferase activity as a marker of cancer cachexia in mice bearing colon 26 adenocarcinoma. Jpn J Cancer Res 89:649-056.
14. Xu J, Moatamed F, Caldwell JS, Walker JR, Kraiem Z, Taki K, Brent CA, Hershman JM 2003 Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 88:4990-4996.
15. Markert JM, Fuller CM, Gillespie GY, Bubien JK, McLean LA, Hong RL, Lee K, Gullans SR, Mapstone TB, Benos DJ 2001 Differential gene expression profiling in human brain tumors. Physiol Genomics 5:21-33.
16. Kassem HSh, Sangar V, Cowan R, Clarke N, Margison GP 2002 A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer 101:454-460.
17. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, Ohki M, Yasugi T, Taketani Y, Hirohashi S 2003 Expression profiling in ovarian clear cell carcinoma: Identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163:2503-2512.
18. Yao M, Tabuchi H, Nagashima Y, Baba M, Nakaigawa N, Ishiguro H, Hamada K, Inayama Y, Kishida T, Hattori K, Yamada-Okabe H, Kubota Y 2005 Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol 205:377-387.
19. Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW 2004 The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res 14:491-599.
20. Xu J, Capezzone M, Xu X, Hershman JM 2005 Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells. Mol Endocrinol. 19:527-539.
21. Rey-Campos J, Chouard T, Yaniv M, Cereghini S 1991 vHNF1 is a homeoprotein that activates transcription and forms heterodimers with HNF1. EMBO J 10:1445-1457.
22. Bach I, Mattel MC, Cereghini S, Yaniv M 1991 Two members of an HNF1 homeoprotein family are expressed in human liver. Nucleic Acids Res 19:3553-3559.
23. Coffinier C, Barra J, Babinet C, Yaniv M 1999 Expression of the vHNF1/HNF1beta homeoprotein gene during mouse organogenesis. Mech Dev 89:211-213.
24. Serfas MS, Tyner AL. 1993 HNF-1 alpha and HNF-1 beta expression in mouse intestinal crypts. Am J Physiol 265: G506-513.
25. Bai Y, Pontoglio M, Hiesberger T, Sinclair AM, Igarashi P 2002 Regulation of kidney-specific Ksp-cadherin gene promoter by hepatocyte nuclear factor-1beta. Am J Physiol Renal Physiol 283:F839-851.
26. Boudreau F, Zhu Y, Traber PG 2001 Sucrase-isomaltase gene transcription requires the hepatocyte nuclear factor-1 (HNF-1) regulatory element and is regulated by the ratio of HNF-1 alpha to HNF-1beta. J Biol Chem 276:32122-32128.
27. Hu C, Perlmutter DH 2002 Cell-specific involvement of HNF-1beta in alpha(1)-antitrypsin gene expression in human respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol 282:L757-765.
28. Song YH, Ray K, Liebhaber SA, Cooke NE 1998 Vitamin D-binding protein gene transcription is regulated by the relative abundance of hepatocyte nuclear factors 1alpha and 1beta. J Biol Chem 273:28408-28418.
29. Soubt MK, Marksitzer R, Menoud PA, Nagamine Y 1998 Role of tissue-specific transcription factor LFB3 in a cyclic AMP-responsive enhancer of the urokinase-type plasminogen activator gene in LLC-PK1 cells. Mol Cell Biol 18:4698-4706.
30. Ryffel GU 2001 Mutations in the human genes encoding the transcription factors of the hepatocyte nuclear factor (HNF)1 and HNF4 families: functional and pathological consequences. J Mol Endocrinol 27:11-29.
31. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, Lindner T, Yamagata K, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Iwamoto Y, Bell GI 1997 Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 17:384-385.
32. Lindner TH, Njolstad PR, Horikawa Y, Bostad L, Bell GI, Sovik O 1999 A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. Hum Mol Genet 8:2001-2008.
33. Grunstein M 1997 Histone acetylation in chromatin structure and transcription. Nature 389:349-352.
34. Piekarz R, Bates S 2004 A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 10:2289-2298.
35. Vigushin DM 2002 FR-901228 Fujisawa/National Cancer Institute. Curr Opin Investig Drugs 3:1396-402.
36. Ohta K, Pang XP, Berg L, Hershman JM 1997 Growth inhibition of new human thyroid carcinoma cell lines by activation of adenylate cyclase through the beta-adrenergic receptor. J Clin Endocrinol Metab 82:2633-2638.
37. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T 2004 Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865-2875.
38. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T 2001 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/1(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86:3430-3435.
39. Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F, Ringert RH 2004 Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol 24:25-31.
40. Laribee RN, Klemsz MJ 2001 Loss of PU.1 expression following inhibition of histone deacetylases. J Immunol 167:5160-5166.
41. Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S 2005 Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69:603-616.
42. Chiba T, Yokosuka O, Fukai K, Kojima H, Tada M, Arai M, Imazeki F, Saisho H 2004 Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology 66:481-491.
43. Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K 2004 Expression profiling of sodium butyrate (NaB)-treated cells: Identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene 23:6304-6315.
44. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S 2003 Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett 195:161-168.
45. Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S 2003 Antitumor efficacy of FK228, a novel historic dencetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 66:897-906.
46. Ferguson M, Henry PA, Currie RA 2003 Historic deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene. Nucleic Acids Res 31:3123-3133.
47. Dehm SM, Bonham K 2004 SRC gene expression in human cancer: The role of transcriptional activation. Biochem Cell Biol 82:263-274.
48. Yu X, Guo ZS, Marcu MC, Neckers L, Nguyen DM, Chen GA, Schrump DS 2002 Modulation of p53/ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 94:504-513.
49. Mie Lee Y, Kim SH, Kim HS, Jin Son M, Nakajima H, Jeong Kwon H, Kim KW 2003 Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem Biophys Res Commun 300:241-246.